Skip to main content
    S

    Shuttle Pharmaceuticals Inc (SHPH)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $4.24
    -0.29 (-6.40%)

    Market Cap: $21.58M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Shuttle Pharmaceuticals Inc (SHPH) Financials: Revenue, Profit and Cash Flow

    Updated Sep 24, 2026. Financial statements from company filings, amounts in US dollars.

    Shuttle Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$11.72M, operating cash flow was -$9.48M and free cash flow was -$12.53M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of -$3.15M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $11.92M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2018N/AN/AN/AN/AN/A
    Dec 2017N/AN/AN/AN/AN/A
    Dec 2016N/AN/AN/AN/AN/A
    Dec 2015N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2015 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2018Dec 2017Dec 2016Dec 2015
    Cost of revenue$0$0$0$0$0$54.95K$18.00K$18.74KN/AN/A
    Gross profit$0$0$0$0$0-$54.95K-$18.00K-$18.74KN/AN/A
    Research and development$4.05M$3.62M$3.52M$1.05M$1.02M$161.77K$55.57K$836$0$0
    Operating income-$11.92M-$7.70M-$5.89M-$2.34M-$1.74M-$509.52K-$586.63K-$203.89KN/AN/A
    Net income-$11.72M-$9.14M-$6.59M-$5.00M-$1.15M-$805.73K-$626.14K-$213.59KN/AN/A
    EBITDA-$11.64M-$6.92M-$2.06MN/A-$1.04MN/A-$577.22K-$183.97KN/AN/A
    Fiscal years ended Dec 2015 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$0$0$0$0$0$0$5.75K$0$0$0$9.66K$0
    Gross profit$0$0-$289.07K$0$0$0-$1.80K$0$0$0-$1.98K$0
    Operating income-$3.95M-$2.22M-$2.79M-$2.27M-$3.91M-$2.95M-$1.78M-$3.05M-$1.48M-$1.38M-$1.28M-$1.60M
    Net income-$3.15M-$2.15M-$2.61M-$2.35M-$3.71M-$3.05M-$1.60M-$3.78M-$2.03M-$1.73M-$1.64M-$1.79M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, short-term debt of $2.00M exceeded cash and equivalents by $1.67M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2018Dec 2017Dec 2016Dec 2015
    Total assets$10.48M$2.51M$5.95M$8.65M$651.64K$544.05K$621.27K$121.30KN/AN/A
    Current assets$502.91K$2.21M$5.59M$8.58M$509.62K$341.19K$613.96K$102.46K$115.93K$200.21K
    Cash and equivalents$334.00K$1.92M$2.58M$8.42M$504.75K$117.15K$352.39K$50.71KN/AN/A
    Total liabilities$8.22M$1.80M$1.90M$975.68K$2.28M$2.23M$593.82K$405.65KN/AN/A
    Short-term debt$2.00M$190.27K$596.00K$685.47K$849.50K$744.91K$400.00K$314.38KN/AN/A
    Long-term debtN/AN/A$135.09K$0N/AN/AN/AN/AN/AN/A
    Shareholder equity$2.25M$709.15K$4.06M$7.68M-$1.63M-$1.69M$27.46K-$284.35KN/AN/A
    Fiscal years ended Dec 2015 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$22.81M$11.81M$10.48M$3.54M$5.50M$5.31M$2.51M$673.57K$2.81M$4.75M$5.95M$7.38M
    Total liabilities$3.63M$8.46M$8.22M$2.15M$1.90M$2.02M$1.80M$1.99M$2.01M$1.99M$1.90M$1.77M
    Cash and equivalents$90.24K$1.09M$334.00K$2.09M$4.82M$4.51M$1.92M$156.66K$695.59K$1.40M$2.58M$3.89M
    Shareholder equity$19.18M$3.35M$2.25M$1.39M$3.61M$3.29M$709.15K-$1.32M$801.43K$2.76M$4.06M$5.61M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2018Dec 2017Dec 2016Dec 2015
    Operating cash flow-$9.48M-$7.33M-$5.58M-$2.67M-$300.34K-$26.83K-$566.69K-$202.71K-$230.07K-$303.55K
    Capital expenditures$3.04M$0$19.05K$0$4$10.82K$10.82K$0$4.55K$4.55K
    Free cash flow-$12.53M-$7.33M-$5.60M-$2.67M-$300.34K-$37.65K-$577.51K-$202.71K-$234.63K-$308.11K
    Dividends paid$0$0N/A$402.07KN/AN/AN/AN/AN/AN/A
    Share repurchases$557.66K$235.71KN/AN/AN/AN/AN/AN/AN/AN/A
    Investing cash flow-$3.06M$2.92M-$2.83M$0$0-$10.82K-$10.82KN/A$20.17K$25.43K
    Financing cash flow$10.95M$3.76M$2.57M$10.58M$687.93K$70.07K$868.37K$160.62K$173.86K$300.00K
    Fiscal years ended Dec 2015 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$567.64K-$2.42M-$973.01K-$2.63M-$3.36M-$2.53M-$2.69M-$2.00M-$1.40M-$1.24M-$1.06M-$1.53M
    Capital expendituresN/A$36.00K$0$4$0$0$2$2$2$3$4$19.05K
    Free cash flowN/A-$2.45M-$973.01K-$2.63M-$3.36M-$2.53M-$2.69M-$2.00M-$1.40M-$1.24M-$1.06M-$1.55M
    Last 12 quarters

    Frequently Asked Questions About SHPH

    What is Shuttle Pharmaceuticals' annual revenue?

    Shuttle Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Shuttle Pharmaceuticals profitable?

    No. Shuttle Pharmaceuticals reported net income of -$11.72M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does SHPH generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$9.48M minus capital expenditures of $3.04M produced free cash flow of -$12.53M.

    How much debt does Shuttle Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $2.00M and cash and equivalents of $334.00K.